Diagnostic guidelines don't catch all rare cancers, study finds
The diagnostic guidelines used to identify two distinct subsets of T-cell lymphomas—the leukemic variant Sézary syndrome and ...
Innate Pharma Reports First Half 2024 Business Update and Financial Results
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results for the six ...
Pharmaceutical Technology15 天
Nivolumab by Bristol-Myers Squibb for Metastatic Uveal Melanoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Uveal Melanoma.
Pharmaceutical Technology15 天
Romidepsin by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
Romidepsin (Istodax) is an antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous administration. Istodax is approved for the treatment of cutaneous T-cell lymphoma ...
Innate Pharma S.A. (NASDAQ:IPHA) Q2 2024 Earnings Call Transcript
Q2 2024 Earnings Call Transcript September 12, 2024 Operator: Thank you for standing by, and welcome to the Innate Pharma ...
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium
Northvale, New Jersey-- (Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, ...